• VB4-P5 – novel new chemical entity with potential to address significant unmet need in rare and large-market chronic kidney disease • CALGARY, Alberta, April 13, 2026 (GLOBE NEWSWIRE) -- XORTX ...
Acquisition includes novel new chemical entity VB4-P5 with potential to address significant unmet needs in rare and large-market kidney diseases Dr. Allen Davidoff, Chief Executive Officer of XORTX, ...
• VB4-P5 - novel new chemical entity with potential to address significant unmet need in rare and large-market chronic kidney disease • The Program includes a novel new chemical entity, VB4-P5, along ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results